News.
Press releases are issued via TMX Newsfile and archived here. Sign up for email alerts to receive releases directly.
012026
Optimi Completes First Commercial Shipment of GMP MDMA
First commercial shipment of GMP-certified MDMA capsules departs Princeton facility for a regulated access program partner.
Optimi Reports Q2 2026 Financial Results
Second quarter revenue growth driven by expanded GMP psilocybin shipments and DEL-amended product mix.
Health Canada Grants DEL Amendment for Expanded Psilocybin Analogs
Dealer's Licence amendment permits manufacture and distribution of an expanded set of psilocybin analogs.
Optimi Graduates to OTCQX Best Market
U.S. listing upgraded from OTCQB Venture Market to OTCQX Best Market under the symbol OPTHF.
022025
Optimi Completes Princeton Facility Expansion
Capacity at the Princeton GMP facility expanded to support commercial-scale MDMA and psilocybin supply.
Optimi Reports Fiscal Year 2025 Results
Full-year revenue, gross margin expansion, and a strengthened balance sheet heading into fiscal 2026.